

Supporting Information for

## Near-Infrared Light-Responsive Nitric Oxide Delivery Platform for Enhanced Radioimmunotherapy

Xuanfang Zhou<sup>1</sup>, Zhouqi Meng<sup>1,\*</sup>, Jialin She<sup>1</sup>, Yaojia Zhang<sup>1</sup>, Xuan Yi<sup>2</sup>, Hailin Zhou<sup>2</sup>, Jing Zhong<sup>2</sup>, Ziliang Dong<sup>1</sup>, Xiao Han<sup>1</sup>, Muchao Chen<sup>1</sup>, Qin Fan<sup>1</sup>, Kai Yang<sup>2</sup>, Chao Wang<sup>1,\*</sup>

<sup>1</sup>Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-based Functional Materials and Devices, Soochow University, Suzhou, Jiangsu 215123, People's Republic of China


<sup>2</sup>State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, Jiangsu 215123, People's Republic of China

\*Corresponding authors. E-mail: cwang@suda.edu.cn (Chao Wang), mengzhouqi@gmail.com (Zhouqi Meng)


### Supplementary Table and Figures

**Table S1** Hemolysis ratio of the nanoparticle's solution compared with negative and positive control (3 samples in each group)


	Negative control	Positive control	Ag <sub>2</sub> S@BSA-SNO (5 mg mL <sup>-1</sup> )	Ag <sub>2</sub> S@BSA-SNO (10 mg mL <sup>-1</sup> )	Ag <sub>2</sub> S@BSA-SNO (20 mg mL <sup>-1</sup> )
<b>Absorbance intensity</b>	0.061±0.001	1.422±0.016	0.065±0.002	0.069±0.007	0.081±0.006
<b>Hemolysis</b>	-	-	0.293%	0.612%	1.4%




**Fig. S1** Colloidal stability of Ag<sub>2</sub>S@BSA-SNO nanoparticles in one week




**Fig. S2** Characteristics of our nanoparticles. (a) Fluorescence of Ag<sub>2</sub>S@BSA-SNO solution. (b) TEM image of Ag<sub>2</sub>S@OVA-SNO nanoparticles




**Fig. S3** *In vitro* therapeutic efficiency of our nanoparticles. MTT data of Ag<sub>2</sub>S@BSA-SNO nanoparticles after being incubated with materials 24 h




**Fig. S4** *In vitro* therapeutic efficiency of our nanoparticles. (a) DNA damage staining of cells under different dose and material concentration treatments. Red:  $\gamma$ -H2AX signal (DNA damage); Blue: DAPI (nuclear staining). (b) Confocal image of AM/PI double stained experiments. Green: AM staining (live cells); red: PI staining (dead cells)



**Fig. S5** (a) PA image of PBS group. (b) Bio-distribution of  $\text{Ag}_2\text{S}@BSA\text{-SNO}$ . (c) Blood circulation of  $\text{Ag}_2\text{S}@BSA\text{-SNO}$  nanoparticles after intravenous injection. The concentrations are determined by element Ag



**Fig. S6** Hypoxia staining of tumor tissue after various treatments. **(a)** Confocal images of tumor sections Green: hypoxia probe; red: anti-CD31 antibody (blood vessels); blue: DAPI (nuclear staining). **(b)** Statistic data of hypoxia area in the confocal image



**Fig. S7** H&E staining of various tissue sections from different mice